Although the exact mechanism underlying the anti-obesity effect of GIP or the GIPR system is unclear, cumulative results support that the therapeutic effect associated with the modulation of the GIP system is mediated by the central nervous system (CNS) [1]. The gene discussed is GIP; the disease is obesity due to melanocortin 4 receptor deficiency.